Breaking News

INOVIO to Develop dMAb COVID Treatments under DARPA Grant

$37.6 million grant will leverage AstraZeneca's monoclonal antibody and INOVIO's dMAb technologies in the fight against COVID-19.

By: Contract Pharma

Contract Pharma Staff

INOVIO and a team of scientists from The Wistar Institute, AstraZeneca, the University of Pennsylvania, and Indiana University received a $37.6 million grant from the U.S. Defense Advanced Research Projects Agency (DARPA), to use INOVIO’s DNA-encoded monoclonal antibody (dMAb) technology to develop anti-SARS-CoV-2-specific dMAbs, which could offer versatile capabilities to function as both a therapeutic and preventive treatment for COVID-19. As part of DARPA’s two-year grant, INO...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters